Orthocell Limited (ASX:OCC)

Market Cap	327.30M
Revenue (ttm)	6.31M
Net Income (ttm)	-3.25M
Shares Out	243.34M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,156,288
Average Volume	861,807
Open	1.250
Previous Close	1.240
Day's Range	1.250 - 1.370
52-Week Range	0.350 - 1.790
Beta	0.22
RSI	59.48
Earnings Date	Aug 29, 2025

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OCC

Financial Performance

In 2024, Orthocell's revenue was 5.32 million, an increase of 25.27% compared to the previous year's 4.24 million. Losses were -7.18 million, 14.9% more than in 2023.